ARCHIVES

FDA cancer therapeutics review split among three units in reorganization.

This article is from The Cancer Letter archive.

Vol. 29 No. 37 | October 10, 2003

Download PDF Visit The Full Archive

Related Articles

Imbruvica Improves PFS, OS In Phase III CLL Study

December 26, 2014

In Congress: Gore, Democrats Rally For Anti-Tobacco Legislation

February 20, 1998

Without Advance Directives, Families Prolong Treatment

April 27, 2001

Fountain Displays Some Statesmanship

July 8, 1977

FDA Approves Abraxane For Second-Line Treatment Of Metastatic Breast Cancer

January 28, 2005

Cooperative Group chairmen Cool, But High Priority Trials To Continue

January 18, 1991